Vyome Holdings

Business news, market intelligence, and global industry analysis.

The Latest

Samsung Galaxy M17 5G review: Is this budget Samsung phone worth buying at ₹15,498?

Samsung Galaxy M17 5G at ₹15,498: Hidden budget beast or just another overhyped Samsung phone?

Representative image of a Boeing C-17 Globemaster III during maintenance, illustrating Boeing’s $166.8 million landing gear spares contract modification and the growing strategic importance of military airlift sustainment.

Why Boeing’s $166.8 m C-17 spares win could matter more than it looks for BA stock

Why selective immune homeostasis is the bigger story behind CUE-401

Nida Khan in TCS Nashik case: Designation disputed, pregnancy cited for bail, police deploy four teams in ongoing manhunt

Vyome completes merger with ReShape Lifesciences, to debut on Nasdaq as Vyome Holdings (HIND) on August 15

Vyome merges with ReShape Lifesciences, will trade on Nasdaq as Vyome Holdings (HIND) from August 15, focusing on immuno-inflammatory and rare diseases.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

August 15, 2025